TTM’s $1B Quarter Hides a Margin Mirage and a CEO-Shaped Hole

Continue Reading With a Free Account

Create a free account to see the full scanned list, new entries and chart analysis. No card needed.

Create Free AccountContinue With Google

Already registered? Sign in

TTM Technologies just posted a headline number that would make any CEO blush: $1.00 billion in Q2 2026 sales, up 37% year-over-year, with non-GAAP EPS of $0.99 beating estimates by nearly 11%. Management raised full-year guidance to $4.4 billion in sales and $5.00 in EPS. The stock popped 3.89% in after-hours trading. But beneath the surface of this ‘record’ quarter lies a far more uncomfortable story: the company’s core profitability is actually shrinking relative to its own recent past, and the man who built this AI-era growth story is already out the door.

1. the Lede and the Real Story

Compare the quarters. In Q1 2026, TTM grew revenue 30% to $846 million and delivered $0.75 EPS. In Q2, revenue grew 37% to $1.0 billion, but EPS only grew from $0.75 to $0.99 — a 32% increase. Revenue growth accelerated, yet EPS growth decelerated. That is the tell. The company is spending more to generate each dollar of sales, and the incremental margin on that extra $154 million in revenue was far lower than what investors should expect from a ‘scaling’ business. The real story is not the top line; it is the deteriorating conversion of revenue into profit and the leadership vacuum at the top.

Inside the Full Analysis

  • 🔒2. The Negative Space — What They Didn’t Say
  • 🔒3. Script vs. Reality
  • 🔒4. Evasion Tactics & The Hot Seat
  • 🔒5. Excuses vs. Execution
  • 🔒6. The CANSLIM Check
  • 🔒The Bottom Line

About CANSLIM Research

CANSLIM Research is an independent project using AI to analyze global financial data by applying rule-based algorithms derived from well-known momentum traders. Our AI personas—simulations inspired by these methods with no trader affiliation or endorsement—scan stocks, analyze charts, track sector rotation, and publish educational insights under human oversight. Support via contributions, sponsorship, or partnership never buys stock-specific access, influences publishing, or involves paid security features. We are not a registered charity.

Disclaimer: All content is strictly educational—not investment advice, recommendations, or buy/sell solicitations. CANSLIM Research is not a licensed adviser or analyst under any regulatory body (including SEC, FINRA, SFC, FCA, SEBI, or EU authorities under ESMA). Investing carries risk of total loss, and past performance does not predict future results. Consult a licensed financial adviser before investing.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.